vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Nextdoor Holdings, Inc. (NXDR). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $69.5M, roughly 1.1× Nextdoor Holdings, Inc.). Nextdoor Holdings, Inc. runs the higher net margin — -5.8% vs -121.9%, a 116.1% gap on every dollar of revenue. On growth, Nextdoor Holdings, Inc. posted the faster year-over-year revenue change (6.5% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $9.4M). Over the past eight quarters, Nextdoor Holdings, Inc.'s revenue compounded faster (14.3% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Nextdoor Holdings, Inc. is an American company that operates a hyperlocal social networking service for neighborhoods. The company was founded in 2008 and is based in San Francisco, California. Nextdoor launched in the United States in October 2011. It is available in eleven countries as of May 2023. In 2024, the company claimed to have 88 million "neighbors" as members.

HCAT vs NXDR — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.1× larger
HCAT
$74.7M
$69.5M
NXDR
Growing faster (revenue YoY)
NXDR
NXDR
+12.7% gap
NXDR
6.5%
-6.2%
HCAT
Higher net margin
NXDR
NXDR
116.1% more per $
NXDR
-5.8%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$245.0K more FCF
HCAT
$9.6M
$9.4M
NXDR
Faster 2-yr revenue CAGR
NXDR
NXDR
Annualised
NXDR
14.3%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
NXDR
NXDR
Revenue
$74.7M
$69.5M
Net Profit
$-91.0M
$-4.0M
Gross Margin
84.9%
Operating Margin
-115.3%
-10.7%
Net Margin
-121.9%
-5.8%
Revenue YoY
-6.2%
6.5%
Net Profit YoY
-340.3%
66.7%
EPS (diluted)
$-1.29
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
NXDR
NXDR
Q4 25
$74.7M
$69.5M
Q3 25
$76.3M
$68.9M
Q2 25
$80.7M
$65.1M
Q1 25
$79.4M
$54.2M
Q4 24
$79.6M
$65.2M
Q3 24
$76.4M
$65.6M
Q2 24
$75.9M
$63.3M
Q1 24
$74.7M
$53.1M
Net Profit
HCAT
HCAT
NXDR
NXDR
Q4 25
$-91.0M
$-4.0M
Q3 25
$-22.2M
$-12.9M
Q2 25
$-41.0M
$-15.4M
Q1 25
$-23.7M
$-22.0M
Q4 24
$-20.7M
$-12.1M
Q3 24
$-14.7M
$-14.9M
Q2 24
$-13.5M
$-42.8M
Q1 24
$-20.6M
$-28.3M
Gross Margin
HCAT
HCAT
NXDR
NXDR
Q4 25
84.9%
Q3 25
52.6%
84.9%
Q2 25
83.6%
Q1 25
82.6%
Q4 24
84.0%
Q3 24
47.5%
83.0%
Q2 24
83.8%
Q1 24
81.2%
Operating Margin
HCAT
HCAT
NXDR
NXDR
Q4 25
-115.3%
-10.7%
Q3 25
-22.9%
-25.0%
Q2 25
-46.0%
-31.1%
Q1 25
-25.4%
-49.9%
Q4 24
-22.0%
-26.2%
Q3 24
-17.9%
-31.7%
Q2 24
-20.8%
-77.4%
Q1 24
-30.5%
-65.4%
Net Margin
HCAT
HCAT
NXDR
NXDR
Q4 25
-121.9%
-5.8%
Q3 25
-29.1%
-18.7%
Q2 25
-50.8%
-23.6%
Q1 25
-29.9%
-40.5%
Q4 24
-26.0%
-18.6%
Q3 24
-19.3%
-22.7%
Q2 24
-17.8%
-67.6%
Q1 24
-27.6%
-53.2%
EPS (diluted)
HCAT
HCAT
NXDR
NXDR
Q4 25
$-1.29
$-0.01
Q3 25
$-0.32
$-0.03
Q2 25
$-0.59
$-0.04
Q1 25
$-0.35
$-0.06
Q4 24
$-0.33
$-0.03
Q3 24
$-0.24
$-0.04
Q2 24
$-0.23
$-0.11
Q1 24
$-0.35
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
NXDR
NXDR
Cash + ST InvestmentsLiquidity on hand
$95.7M
$63.3M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$431.3M
Total Assets
$502.6M
$486.8M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
NXDR
NXDR
Q4 25
$95.7M
$63.3M
Q3 25
$91.5M
$56.1M
Q2 25
$97.3M
$62.0M
Q1 25
$342.0M
$57.3M
Q4 24
$392.0M
$45.5M
Q3 24
$387.3M
$49.7M
Q2 24
$308.3M
$53.0M
Q1 24
$327.8M
$69.7M
Total Debt
HCAT
HCAT
NXDR
NXDR
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
NXDR
NXDR
Q4 25
$245.8M
$431.3M
Q3 25
$331.9M
$429.7M
Q2 25
$347.5M
$429.5M
Q1 25
$376.8M
$436.1M
Q4 24
$365.2M
$453.5M
Q3 24
$355.0M
$456.0M
Q2 24
$357.0M
$472.3M
Q1 24
$357.2M
$541.4M
Total Assets
HCAT
HCAT
NXDR
NXDR
Q4 25
$502.6M
$486.8M
Q3 25
$587.1M
$488.9M
Q2 25
$616.2M
$490.4M
Q1 25
$891.5M
$495.0M
Q4 24
$858.9M
$514.0M
Q3 24
$813.0M
$517.7M
Q2 24
$691.7M
$542.1M
Q1 24
$695.1M
$633.1M
Debt / Equity
HCAT
HCAT
NXDR
NXDR
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
NXDR
NXDR
Operating Cash FlowLast quarter
$9.9M
$9.5M
Free Cash FlowOCF − Capex
$9.6M
$9.4M
FCF MarginFCF / Revenue
12.9%
13.5%
Capex IntensityCapex / Revenue
0.4%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$5.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
NXDR
NXDR
Q4 25
$9.9M
$9.5M
Q3 25
$-464.0K
$-6.3M
Q2 25
$-9.0M
$2.9M
Q1 25
$280.0K
$368.0K
Q4 24
$-3.5M
$11.8M
Q3 24
$6.2M
$-13.0M
Q2 24
$1.6M
$-5.4M
Q1 24
$10.3M
$-13.6M
Free Cash Flow
HCAT
HCAT
NXDR
NXDR
Q4 25
$9.6M
$9.4M
Q3 25
$-719.0K
$-6.5M
Q2 25
$-9.2M
$2.6M
Q1 25
$-390.0K
$340.0K
Q4 24
$-3.9M
$11.7M
Q3 24
$5.5M
$-13.2M
Q2 24
$1.3M
$-5.5M
Q1 24
$10.1M
$-13.6M
FCF Margin
HCAT
HCAT
NXDR
NXDR
Q4 25
12.9%
13.5%
Q3 25
-0.9%
-9.4%
Q2 25
-11.4%
4.1%
Q1 25
-0.5%
0.6%
Q4 24
-4.9%
17.9%
Q3 24
7.2%
-20.1%
Q2 24
1.7%
-8.6%
Q1 24
13.5%
-25.7%
Capex Intensity
HCAT
HCAT
NXDR
NXDR
Q4 25
0.4%
0.1%
Q3 25
0.3%
0.2%
Q2 25
0.3%
0.5%
Q1 25
0.8%
0.1%
Q4 24
0.5%
0.1%
Q3 24
0.9%
0.3%
Q2 24
0.4%
0.2%
Q1 24
0.3%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

NXDR
NXDR

US$67.1M97%
Non Us$2.3M3%

Related Comparisons